Cargando…

Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease

BACKGROUND AND OBJECTIVE: Pompe disease (PD) is an inherited lysosomal storage disease that progresses with glycogen accumulation in many tissues, due to the deficiency of the acid-alpha glucosidase enzyme. Recombinant alglucosidase alfa (rhGAA) is the only disease-specific treatment option, in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ertoy Karagol, Hacer Ilbilge, Inci, Asli, Terece, Sinem Polat, Kilic, Ayse, Demir, Fevzi, Yapar, Dilek, Koken, Gizem, Okur, Ilyas, Ezgu, Fatih Suheyl, Tumer, Leyla, Bakirtas, Arzu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Clinical Allergy − Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137310/ https://www.ncbi.nlm.nih.gov/pubmed/36623499 http://dx.doi.org/10.1159/000528343

Ejemplares similares

New Perspectives in the Management of Mild to Moderate Asthma in Children
por: Ertoy Karagol, Hacer Ilbilge, et al.
Publicado: (2021)

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
por: Beck, Michael
Publicado: (2009)

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Two Cases of Esophageal Eosinophilia: Eosinophilic Esophagitis or Gastro-Esophageal Reflux Disease?
por: Yilmaz, Ozlem, et al.
Publicado: (2014)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
por: Zhu, Diqi, et al.
Publicado: (2022)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa
por: Baek, Rena C., et al.
Publicado: (2016)

Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series
por: İnci, Aslı, et al.
Publicado: (2021)

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
por: van Gelder, C. M., et al.
Publicado: (2016)

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV
por: Yi, Haiqing, et al.
Publicado: (2016)

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
por: Kishnani, Priya, et al.
Publicado: (2017)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
por: Toscano, Antonio, et al.
Publicado: (2022)

Double dose alglucosidase-alpha doubles benefit?
por: Finsterer, Josef, et al.
Publicado: (2018)

Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
por: Huffaker, Michelle F., et al.
Publicado: (2019)

A Case of Glycogen Storage Disease Type 1a Mimicking Familial Chylomicronemia Syndrome
por: Olgac, A, et al.
Publicado: (2021)

Correction to: Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization.
Publicado: (2020)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
por: Byrne, Barry J., et al.
Publicado: (2017)

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
por: Dimachkie, Mazen M., et al.
Publicado: (2022)

Desensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent
por: Demirel, Fevzi, et al.
Publicado: (2015)

Citrullinemia with an Atypical Presentation: Paroxysmal Hypoventilation Attacks
por: Öztürk, Zeynep, et al.
Publicado: (2018)

A Myopathy, Lactic Acidosis, Sideroblastic Anemia (MLASA) Case Due to a Novel PUS1 Mutation
por: Kasapkara, Çiğdem Seher, et al.
Publicado: (2017)

Posterior fossa horns; a new calvarial finding of mucopolysaccharidoses with well-known cranial MRI features
por: DAMAR, Çağrı, et al.
Publicado: (2020)

Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
por: Panchal, Hemali, et al.
Publicado: (2023)

Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy
por: Landis, Jesa L., et al.
Publicado: (2018)

Evaluation of Forensic Cases in the Pediatric Intensive Care Unit
por: Polat, Sinem, et al.
Publicado: (2021)

A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B
por: Muschol, Nicole, et al.
Publicado: (2023)

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
por: Tiraboschi, Gilles, et al.
Publicado: (2023)

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
por: Kishnani, Priya S., et al.
Publicado: (2023)

Pompes turbomoleculaires
por: Versolatto, B
Publicado: (1982)

The role of IFIH1 gene rs1990760 and rs2111485 single-nucleotide polymorphisms in generalized vitiligo predisposition
por: ONAN, Duru, et al.
Publicado: (2019)

Characteristics of Pompe disease in China: a report from the Pompe registry
por: Zhao, Yuying, et al.
Publicado: (2019)

A 7-year-old Boy with Hand Tremors and a Novel Mutation for L-2-hydroxyglutaric Aciduria
por: Olgac, A, et al.
Publicado: (2019)

Secondary Hemophagocytosis in Propionic Acidemia
por: Kasapkara, Cigdem Seher, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tfepivl7uea81mniiv1gokofu9